{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T01:27:23Z","timestamp":1791509243922,"version":"4.3.4"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T00:00:00Z","timestamp":1671667200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T00:00:00Z","timestamp":1671667200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005760","name":"University of Gothenburg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005760","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>Cerebrospinal fluid (CSF) tau biomarkers are reliable diagnostic markers for Alzheimer\u2019s disease (AD). However, their strong association with amyloid pathology may limit their reliability as specific markers of tau neurofibrillary tangles. A recent study showed evidence that a ratio of CSF C-terminally truncated tau (tau368, a tangle-enriched tau species), especially in ratio with total tau (t-tau), correlates strongly with tau PET tracer uptake. In this study, we set to evaluate the performance of the tau368\/t-tau ratio in capturing tangle pathology, as indexed by a high-affinity tau PET tracer, as well as its association with severity of clinical symptoms.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In total, 125 participants were evaluated cross-sectionally from the Translational Biomarkers of Aging and Dementia (TRIAD) cohort (21 young, 60 cognitively unimpaired [CU] elderly [15 A\u03b2+], 10 A\u03b2+ with mild cognitive impairment [MCI], 14 AD dementia patients, and 20 A\u03b2\u2212 individuals with non-AD cognitive disorders). All participants underwent amyloid and tau PET scanning, with [<jats:sup>18<\/jats:sup>F]-AZD4694 and [<jats:sup>18<\/jats:sup>F]-MK6240, respectively, and had CSF measurements of p-tau181, p-tau217, and t-tau. CSF concentrations of tau368 were quantified in all individuals with an<jats:italic>in-house<\/jats:italic>single molecule array assay.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>CSF tau368 concentration was not significantly different across the diagnostic groups, although a modest increase was observed in all groups as compared with healthy young individuals (all<jats:italic>P<\/jats:italic>&lt; 0.01). In contrast, the CSF tau368\/t-tau ratio was the lowest in AD dementia, being significantly lower than in CU individuals (A\u03b2\u2212,<jats:italic>P<\/jats:italic>&lt; 0.001; A\u03b2+,<jats:italic>P<\/jats:italic>&lt; 0.01), as well as compared to those with non-AD cognitive disorders (<jats:italic>P<\/jats:italic>&lt; 0.001). Notably, in individuals with symptomatic AD, tau368\/t-tau correlated more strongly with [<jats:sup>18<\/jats:sup>F]-MK6240 PET SUVR as compared to the other CSF tau biomarkers, with increasing associations being seen in brain regions associated with more advanced disease (isocortical regions &gt; limbic regions &gt; transentorhinal regions). Importantly, linear regression models indicated that these associations were not confounded by A\u03b2 PET SUVr. CSF tau368\/t-tau also tended to continue to become more abnormal with higher tau burden, whereas the other biomarkers plateaued after the limbic stage. Finally, the tau368\/t-tau ratio correlated more strongly with cognitive performance in individuals with symptomatic AD as compared to t-tau, p-tau217 and p-tau181.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The tau368\/t-tau ratio captures novel aspects of AD pathophysiology and disease severity in comparison to established CSF tau biomarkers, as it is more closely related to tau PET SUVR and cognitive performance in the symptomatic phase of the disease.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s13195-022-01142-0","type":"journal-article","created":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T04:21:20Z","timestamp":1671682880000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["CSF tau368\/total-tau ratio reflects cognitive performance and neocortical tau better compared to p-tau181 and p-tau217 in cognitively impaired individuals"],"prefix":"10.1186","volume":"14","author":[{"given":"Joel","family":"Simr\u00e9n","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wagner S.","family":"Brum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J.","family":"Ashton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea L.","family":"Benedet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas K.","family":"Karikari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hlin","family":"Kvartsberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Sjons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Firoza Z.","family":"Lussier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mira","family":"Chamoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenna","family":"Stevenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Hopewell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Pallen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keqiang","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tharick A.","family":"Pascoal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Rosa-Neto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaj","family":"Blennow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,22]]},"reference":[{"issue":"9533","key":"1142_CR1","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/S0140-6736(06)69113-7","volume":"368","author":"K Blennow","year":"2006","unstructured":"Blennow K, de Leon MJ, Zetterberg H. Alzheimer\u2019s disease. Lancet. 2006;368(9533):387\u2013403.","journal-title":"Lancet"},{"issue":"7","key":"1142_CR2","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/S1474-4422(16)00070-3","volume":"15","author":"B Olsson","year":"2016","unstructured":"Olsson B, Lautner R, Andreasson U, et al. CSF and blood biomarkers for the diagnosis of Alzheimer\u2019s disease: a systematic review and meta-analysis. Lancet Neurol. 2016;15(7):673\u201384.","journal-title":"Lancet Neurol"},{"issue":"12","key":"1142_CR3","doi-asserted-by":"publisher","first-page":"e12921","DOI":"10.15252\/emmm.202012921","volume":"12","author":"M Suarez-Calvet","year":"2020","unstructured":"Suarez-Calvet M, Karikari TK, Ashton NJ, et al. Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer\u2019s continuum when only subtle changes in Abeta pathology are detected. EMBO Mol Med. 2020;12(12):e12921.","journal-title":"EMBO Mol Med"},{"key":"1142_CR4","doi-asserted-by":"publisher","first-page":"103836","DOI":"10.1016\/j.ebiom.2022.103836","volume":"76","author":"NJ Ashton","year":"2022","unstructured":"Ashton NJ, Benedet AL, Pascoal TA, et al. Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer\u2019s disease. EBioMedicine. 2022;76:103836.","journal-title":"EBioMedicine"},{"issue":"1","key":"1142_CR5","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1038\/s41467-020-15436-0","volume":"11","author":"S Janelidze","year":"2020","unstructured":"Janelidze S, Stomrud E, Smith R, et al. Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer\u2019s disease. Nat Commun. 2020;11(1):1683.","journal-title":"Nat Commun"},{"key":"1142_CR6","doi-asserted-by":"crossref","unstructured":"Palmqvist S, Insel PS, Stomrud E, et al. Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer\u2019s disease. EMBO Mol Med. 2019;11(12):e11170.","DOI":"10.15252\/emmm.201911170"},{"issue":"4","key":"1142_CR7","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1001\/jamaneurol.2019.4749","volume":"77","author":"PF Meyer","year":"2020","unstructured":"Meyer PF, Pichet Binette A, Gonneaud J, Breitner JCS, Villeneuve S. Characterization of Alzheimer disease biomarker discrepancies using cerebrospinal fluid phosphorylated tau and AV1451 positron emission tomography. JAMA Neurol. 2020;77(4):508\u201316.","journal-title":"JAMA Neurol"},{"issue":"9","key":"1142_CR8","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.15252\/emmm.201707809","volume":"9","author":"N Mattsson","year":"2017","unstructured":"Mattsson N, Scholl M, Strandberg O, et al. (18)F-AV-1451 and CSF T-tau and P-tau as biomarkers in Alzheimer\u2019s disease. EMBO Mol Med. 2017;9(9):1212\u201323.","journal-title":"EMBO Mol Med"},{"issue":"11","key":"1142_CR9","doi-asserted-by":"publisher","first-page":"3517","DOI":"10.1093\/brain\/awab248","volume":"144","author":"TA Pascoal","year":"2021","unstructured":"Pascoal TA, Benedet AL, Tudorascu DL, et al. Longitudinal 18F-MK-6240 tau tangles accumulation follows Braak stages. Brain. 2021;144(11):3517\u201328.","journal-title":"Brain"},{"issue":"24","key":"1142_CR10","doi-asserted-by":"publisher","first-page":"10252","DOI":"10.1073\/pnas.0703676104","volume":"104","author":"YP Wang","year":"2007","unstructured":"Wang YP, Biernat J, Pickhardt M, Mandelkow E, Mandelkow EM. Stepwise proteolysis liberates tau fragments that nucleate the Alzheimer-like aggregation of full-length tau in a neuronal cell model. Proc Natl Acad Sci U S A. 2007;104(24):10252\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"1142_CR11","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s00401-018-1948-2","volume":"137","author":"C Cicognola","year":"2019","unstructured":"Cicognola C, Brinkmalm G, Wahlgren J, et al. Novel tau fragments in cerebrospinal fluid: relation to tangle pathology and cognitive decline in Alzheimer\u2019s disease. Acta Neuropathol. 2019;137(2):279\u201396.","journal-title":"Acta Neuropathol"},{"key":"1142_CR12","doi-asserted-by":"crossref","unstructured":"Horie K, Barthelemy NR, Sato C, Bateman RJ. CSF tau microtubule binding region identifies tau tangle and clinical stages of Alzheimer\u2019s disease. Brain. 2020;144(2):515\u201327.","DOI":"10.1093\/brain\/awaa373"},{"issue":"1","key":"1142_CR13","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1046\/j.1471-4159.1997.68010430.x","volume":"68","author":"GV Johnson","year":"1997","unstructured":"Johnson GV, Seubert P, Cox TM, Motter R, Brown JP, Galasko D. The tau protein in human cerebrospinal fluid in Alzheimer\u2019s disease consists of proteolytically derived fragments. J Neurochem. 1997;68(1):430\u20133.","journal-title":"J Neurochem"},{"issue":"11","key":"1142_CR14","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1038\/nm.3700","volume":"20","author":"Z Zhang","year":"2014","unstructured":"Zhang Z, Song M, Liu X, et al. Cleavage of tau by asparagine endopeptidase mediates the neurofibrillary pathology in Alzheimer\u2019s disease. Nat Med. 2014;20(11):1254\u201362.","journal-title":"Nat Med"},{"issue":"2","key":"1142_CR15","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1093\/brain\/awz346","volume":"143","author":"K Blennow","year":"2020","unstructured":"Blennow K, Chen C, Cicognola C, et al. Cerebrospinal fluid tau fragment correlates with tau PET: a candidate biomarker for tangle pathology. Brain. 2020;143(2):650\u201360.","journal-title":"Brain"},{"issue":"3","key":"1142_CR16","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7(3):263\u20139.","journal-title":"Alzheimers Dement"},{"issue":"2","key":"1142_CR17","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1515\/cclm-2021-0651","volume":"60","author":"J Gobom","year":"2022","unstructured":"Gobom J, Parnetti L, Rosa-Neto P, et al. Validation of the LUMIPULSE automated immunoassay for the measurement of core AD biomarkers in cerebrospinal fluid. Clin Chem Lab Med. 2022;60(2):207\u201319.","journal-title":"Clin Chem Lab Med"},{"key":"1142_CR18","doi-asserted-by":"crossref","unstructured":"Karikari TK, Emersic A, Vrillon A, et al. Head-to-head comparison of clinical performance of CSF phospho-tau T181 and T217 biomarkers for Alzheimer\u2019s disease diagnosis. Alzheimers Dement. 2020;17(5):755\u201367.","DOI":"10.1002\/alz.12236"},{"issue":"1","key":"1142_CR19","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s13195-018-0402-y","volume":"10","author":"TA Pascoal","year":"2018","unstructured":"Pascoal TA, Shin M, Kang MS, et al. In vivo quantification of neurofibrillary tangles with [(18)F]MK-6240. Alzheimers Res Ther. 2018;10(1):74.","journal-title":"Alzheimers Res Ther"},{"key":"1142_CR20","doi-asserted-by":"crossref","unstructured":"Pascoal TA, Therriault J, Benedet AL, et al. 18F-MK-6240 PET for early and late detection of neurofibrillary tangles. Brain. 2020.","DOI":"10.1093\/brain\/awaa180"},{"issue":"3","key":"1142_CR21","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/0197-4580(95)00021-6","volume":"16","author":"H Braak","year":"1995","unstructured":"Braak H, Braak E. Staging of Alzheimer\u2019s disease-related neurofibrillary changes. Neurobiol Aging. 1995;16(3):271\u20138 discussion 8-84.","journal-title":"Neurobiol Aging"},{"key":"1142_CR22","doi-asserted-by":"publisher","first-page":"171","DOI":"10.3389\/fnins.2012.00171","volume":"6","author":"A Klein","year":"2012","unstructured":"Klein A, Tourville J. 101 labeled brain images and a consistent human cortical labeling protocol. Front Neurosci. 2012;6:171.","journal-title":"Front Neurosci"},{"key":"1142_CR23","doi-asserted-by":"crossref","unstructured":"Therriault J, Benedet A, Pascoal TA, et al. Determining amyloid-beta positivity using [(18)F]AZD4694 PET imaging. J Nuclear Med. 2020;62(2):247\u201352.","DOI":"10.2967\/jnumed.120.245209"},{"issue":"2","key":"1142_CR24","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1177\/0049124104268644","volume":"33","author":"KP Burnham","year":"2004","unstructured":"Burnham KP, Anderson DR. Multimodel inference: understanding AIC and BIC in model selection. Sociol Methods Res. 2004;33(2):261\u2013304.","journal-title":"Sociol Methods Res"},{"key":"1142_CR25","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/1471-2105-12-77","volume":"12","author":"X Robin","year":"2011","unstructured":"Robin X, Turck N, Hainard A, et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics. 2011;12:77.","journal-title":"BMC Bioinformatics"},{"issue":"6","key":"1142_CR26","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1016\/j.neuron.2018.02.015","volume":"97","author":"C Sato","year":"2018","unstructured":"Sato C, Barthelemy NR, Mawuenyega KG, et al. Tau kinetics in neurons and the human central nervous system. Neuron. 2018;97(6):1284\u201398 e7.","journal-title":"Neuron"},{"issue":"2","key":"1142_CR27","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s00401-021-02400-5","volume":"143","author":"SA Kaeser","year":"2022","unstructured":"Kaeser SA, Hasler LM, Lambert M, et al. CSF p-tau increase in response to Abeta-type and Danish-type cerebral amyloidosis and in the absence of neurofibrillary tangles. Acta Neuropathol. 2022;143(2):287\u201390.","journal-title":"Acta Neuropathol"},{"issue":"1","key":"1142_CR28","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13195-019-0485-0","volume":"11","author":"O Hansson","year":"2019","unstructured":"Hansson O, Lehmann S, Otto M, Zetterberg H, Lewczuk P. Advantages and disadvantages of the use of the CSF Amyloid beta (Abeta) 42\/40 ratio in the diagnosis of Alzheimer\u2019s Disease. Alzheimers Res Ther. 2019;11(1):34.","journal-title":"Alzheimers Res Ther"},{"issue":"6","key":"1142_CR29","doi-asserted-by":"publisher","first-page":"e14022","DOI":"10.15252\/emmm.202114022","volume":"13","author":"N Mattsson-Carlgren","year":"2021","unstructured":"Mattsson-Carlgren N, Janelidze S, Bateman RJ, et al. Soluble P-tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau. EMBO Mol Med. 2021;13(6):e14022.","journal-title":"EMBO Mol Med"},{"issue":"3","key":"1142_CR30","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/s41591-020-0781-z","volume":"26","author":"NR Barthelemy","year":"2020","unstructured":"Barthelemy NR, Li Y, Joseph-Mathurin N, et al. A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer\u2019s disease. Nat Med. 2020;26(3):398\u2013407.","journal-title":"Nat Med"},{"issue":"6","key":"1142_CR31","doi-asserted-by":"publisher","first-page":"e601","DOI":"10.1212\/WNL.0000000000006875","volume":"92","author":"R Ossenkoppele","year":"2019","unstructured":"Ossenkoppele R, Smith R, Ohlsson T, et al. Associations between tau, Abeta, and cortical thickness with cognition in Alzheimer disease. Neurology. 2019;92(6):e601\u2013e12.","journal-title":"Neurology"},{"issue":"21","key":"1142_CR32","doi-asserted-by":"publisher","first-page":"e2233","DOI":"10.1212\/WNL.0000000000009485","volume":"94","author":"N Mattsson-Carlgren","year":"2020","unstructured":"Mattsson-Carlgren N, Leuzy A, Janelidze S, et al. The implications of different approaches to define AT(N) in Alzheimer disease. Neurology. 2020;94(21):e2233\u2013e44.","journal-title":"Neurology"},{"issue":"8","key":"1142_CR33","doi-asserted-by":"publisher","first-page":"e14398","DOI":"10.15252\/emmm.202114398","volume":"13","author":"R Ossenkoppele","year":"2021","unstructured":"Ossenkoppele R, Reimand J, Smith R, et al. Tau PET correlates with different Alzheimer\u2019s disease-related features compared to CSF and plasma p-tau biomarkers. EMBO Mol Med. 2021;13(8):e14398.","journal-title":"EMBO Mol Med"},{"issue":"12","key":"1142_CR34","doi-asserted-by":"publisher","first-page":"2866","DOI":"10.1007\/s00259-020-04758-2","volume":"47","author":"EE Wolters","year":"2020","unstructured":"Wolters EE, Ossenkoppele R, Verfaillie SCJ, et al. Regional [(18)F]flortaucipir PET is more closely associated with disease severity than CSF p-tau in Alzheimer\u2019s disease. Eur J Nucl Med Mol Imaging. 2020;47(12):2866\u201378.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"1142_CR35","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1007\/s00259-018-4242-6","volume":"46","author":"A Leuzy","year":"2019","unstructured":"Leuzy A, Cicognola C, Chiotis K, et al. Longitudinal tau and metabolic PET imaging in relation to novel CSF tau measures in Alzheimer\u2019s disease. Eur J Nucl Med Mol Imaging. 2019;46(5):1152\u201363.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"7662","key":"1142_CR36","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/nature23002","volume":"547","author":"AWP Fitzpatrick","year":"2017","unstructured":"Fitzpatrick AWP, Falcon B, He S, et al. Cryo-EM structures of tau filaments from Alzheimer\u2019s disease. Nature. 2017;547(7662):185\u201390.","journal-title":"Nature"},{"key":"1142_CR37","doi-asserted-by":"publisher","unstructured":"Horie K, Barth\u00e9lemy NR, Spina S, et al. CSF tau microtubule-binding region identifies pathological changes in primary tauopathies [published online ahead of print, 2022 Nov 24]. Nat Med. 2022. https:\/\/doi.org\/10.1038\/s41591-022-02075-9.","DOI":"10.1038\/s41591-022-02075-9"},{"issue":"18","key":"1142_CR38","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","volume":"384","author":"MA Mintun","year":"2021","unstructured":"Mintun MA, Lo AC, Duggan Evans C, et al. Donanemab in early Alzheimer\u2019s disease. N Engl J Med. 2021;384(18):1691\u2013704.","journal-title":"N Engl J Med"},{"issue":"9","key":"1142_CR39","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1093\/brain\/awx171","volume":"140","author":"M Scholl","year":"2017","unstructured":"Scholl M, Ossenkoppele R, Strandberg O, et al. Distinct 18F-AV-1451 tau PET retention patterns in early- and late-onset Alzheimer\u2019s disease. Brain. 2017;140(9):2286\u201394.","journal-title":"Brain"},{"key":"1142_CR40","doi-asserted-by":"crossref","unstructured":"La Joie R, Visani AV, Baker SL, et al. Prospective longitudinal atrophy in Alzheimer\u2019s disease correlates with the intensity and topography of baseline tau-PET. Sci Transl Med. 2020;12(524):eaau5732.","DOI":"10.1126\/scitranslmed.aau5732"},{"issue":"9","key":"1142_CR41","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/S1474-4422(11)70156-9","volume":"10","author":"ME Murray","year":"2011","unstructured":"Murray ME, Graff-Radford NR, Ross OA, Petersen RC, Duara R, Dickson DW. Neuropathologically defined subtypes of Alzheimer\u2019s disease with distinct clinical characteristics: a retrospective study. Lancet Neurol. 2011;10(9):785\u201396.","journal-title":"Lancet Neurol"},{"issue":"7","key":"1142_CR42","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1001\/archneurol.2011.3758","volume":"69","author":"C Bernick","year":"2012","unstructured":"Bernick C, Cummings J, Raman R, Sun X, Aisen P. Age and rate of cognitive decline in Alzheimer disease: implications for clinical trials. Arch Neurol. 2012;69(7):901\u20135.","journal-title":"Arch Neurol"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-022-01142-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-022-01142-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-022-01142-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,3]],"date-time":"2023-12-03T11:29:51Z","timestamp":1701602991000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-022-01142-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,22]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["1142"],"URL":"https:\/\/doi.org\/10.1186\/s13195-022-01142-0","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,22]]},"assertion":[{"value":"21 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Douglas Institute Research Ethics Board (Protocols: IUSMD 16-60 and 16-61) approved the study, and written informed consent was obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"NA.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. Zetterberg has served at scientific advisory boards and\/or as a consultant for Abbvie, Alector, Annexon, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Novo Nordisk, Pinteon Therapeutics, Red Abbey Labs, Passage Bio, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). KB reported personal fees from Abcam, Axon, Biogen, JOMDD\/Shimadzu, Lilly, MagQu, Novartis, Roche Diagnostics, and Siemens outside the submitted work and being cofounder of Brain Biomarker Solutions in Gothenburg AB, which is a part of the GU Ventures Incubator Program. All other authors report no disclosures.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"192"}}